[go: up one dir, main page]

AR033179A1 - Combinacion de farmacos para inhalacion - Google Patents

Combinacion de farmacos para inhalacion

Info

Publication number
AR033179A1
AR033179A1 ARP020100975A ARP020100975A AR033179A1 AR 033179 A1 AR033179 A1 AR 033179A1 AR P020100975 A ARP020100975 A AR P020100975A AR P020100975 A ARP020100975 A AR P020100975A AR 033179 A1 AR033179 A1 AR 033179A1
Authority
AR
Argentina
Prior art keywords
inhalation
pharmacos
combination
hfa
corticosteroid
Prior art date
Application number
ARP020100975A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR033179A1 publication Critical patent/AR033179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un método para el tratamiento de desordenes respiratorios mediante la administracion por inhalacion de una cantidad efectiva de un agonista del receptor beta 2, una cantidad aceptable de un corticosteroide, y HFA 134a, a un paciente en necesidad del mismo.
ARP020100975A 2001-03-20 2002-03-19 Combinacion de farmacos para inhalacion AR033179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27722901P 2001-03-20 2001-03-20

Publications (1)

Publication Number Publication Date
AR033179A1 true AR033179A1 (es) 2003-12-10

Family

ID=23059937

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100975A AR033179A1 (es) 2001-03-20 2002-03-19 Combinacion de farmacos para inhalacion

Country Status (5)

Country Link
US (3) US20040197271A1 (es)
AR (1) AR033179A1 (es)
BR (1) BR0208012A (es)
IL (1) IL157580A0 (es)
WO (1) WO2002080859A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US7370797B1 (en) * 1996-05-31 2008-05-13 Scott Lindsay Sullivan Pill printing and identification
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0210599A (pt) * 2001-06-21 2004-07-20 Beth Israel Hospital Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
BRPI0307673A2 (pt) * 2002-02-13 2016-11-08 Beth Israel Hospital métodos de tratar doença vascular.
AU2003223562B2 (en) * 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
CA2481972A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
ES2372273T3 (es) 2002-05-17 2012-01-17 Yale University Métodos de tratamiento de la hepatitis.
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
WO2004000368A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
US20100163033A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163020A1 (en) 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for administering an inhalable compound
WO2010107964A1 (en) 2009-03-18 2010-09-23 Pleiades Cardio-Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
PL2435024T3 (pl) * 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9447027B2 (en) * 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
AU2017215189A1 (en) 2016-02-01 2018-08-02 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
KR20200003199A (ko) 2017-05-10 2020-01-08 인카다 테라퓨틱스, 인크. 폐 투여에 의해 심장 병태를 치료하기 위한 단위 용량, 에어로졸, 키트 및 방법
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56138200A (en) * 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
US4423829A (en) * 1980-08-28 1984-01-03 Container Industries Inc. Apparatus for containing and dispensing fluids under pressure and method of manufacturing same
US4387833A (en) * 1980-12-16 1983-06-14 Container Industries, Inc. Apparatus for containing and dispensing fluids under pressure and method of producing same
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2639567B1 (fr) * 1988-11-25 1991-01-25 France Etat Machine a microfaisceau laser d'intervention sur des objets a couche mince, en particulier pour la gravure ou le depot de matiere par voie chimique en presence d'un gaz reactif
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration

Also Published As

Publication number Publication date
IL157580A0 (en) 2004-03-28
WO2002080859A2 (en) 2002-10-17
US20070122351A1 (en) 2007-05-31
US20040197271A1 (en) 2004-10-07
US20070122352A1 (en) 2007-05-31
BR0208012A (pt) 2004-03-02
WO2002080859A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
AR033179A1 (es) Combinacion de farmacos para inhalacion
IL178748A0 (en) Methods for treatment and management of lung cancers using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
AR016217A1 (es) Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept
MXPA05008617A (es) Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
PL376440A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
CA2474479A1 (en) Composition for inhalation
AU2003301190A8 (en) Administration of capsaicinoids
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
AR008293A1 (es) Composicion que comprende una cantidad antihistaminica para el tratamiento de las respuestas alergicas de las vias respiratorias superiores
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
UA87980C2 (ru) Композиция для улучшения познания и памяти
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
SE0102887D0 (sv) New formulation
HRP20050580A2 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
MX2022006537A (es) Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
MD2491F1 (en) Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment
SE0102886D0 (sv) New formulation
AR035503A1 (es) Usos de compuestos que son combinaciones de antagonistas selectivos antagonistas del receptor de dopamina d2 y agonistas selectivos del receptor de 5-ht1a, y las preparaciones farmaceuticas que contienen estos compuestos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal